Payers' costly battle against cancer.

摘要: In a classic managed care struggle between cost containment and physician autonomy, health plans' efforts to rein in the expense of biotech cancer drugs are meeting stiff resistance from oncologists. They staunchly defend their practice buying such marking up prices cover service costs as critical component care. Here's look at issues on both sides.